Retatrutide vs Wegovy: What the 2026 Research Data Actually Shows

Retatrutide produces roughly twice the weight loss of Wegovy in clinical trials — approximately 24–29% body weight reduction versus 14.9% for semaglutide 2.4 mg weekly — making it the most potent obesity pharmacotherapy tested in a phase 3 setting to date. For researchers comparing these two compounds, the mechanistic and efficacy gap is substantial, though the evidence profiles are at very different stages of maturity.

Mechanisms: Triple Agonism vs Single-Receptor GLP-1

Wegovy (semaglutide 2.4 mg) works through a single pathway: GLP-1 receptor agonism that suppresses appetite, slows gastric emptying, and improves glucose-dependent insulin secretion [1]. It's well-characterized, with the STEP-1 trial (NEJM) establishing 14.9% mean weight loss at 68 weeks in adults without diabetes, and the SELECT trial confirming major adverse cardiovascular event (MACE) reduction in patients with established cardiovascular disease.

Retatrutide (LY3437943) adds two more receptor targets — GIP and glucagon — to that GLP-1 backbone [2]. GIP agonism appears to amplify satiety signaling and adipose function beyond what GLP-1 achieves alone, while glucagon receptor activation increases energy expenditure and lipolysis. The GLP-1 component keeps glucagon's hyperglycemic tendency in check. This triple mechanism is why weight-loss curves in retatrutide trials hadn't plateaued by week 48 — researchers noted that "full weight reduction efficacy was not yet attained" at the point treatment stopped [3].

For a deeper look at how dual agonists stack up before adding glucagon receptor engagement, see our breakdown of retatrutide vs tirzepatide for weight loss.

Efficacy Numbers: Phase 2 and Phase 3 Retatrutide Data

The phase 2 trial published in NEJM enrolled 338 adults with obesity and no diabetes across multiple retatrutide dose arms [4]. At 48 weeks, the 12 mg group reached −24.2% mean body weight reduction; 83% of those participants hit ≥15% weight loss and 93% hit ≥10% [3][4]. Placebo produced −2.1%.

Phase 3 data from the TRIUMPH program raised that ceiling further. TRIUMPH-4 (68 weeks, adults with obesity and knee osteoarthritis) reported 28.7% mean weight loss at 12 mg and 26.4% at 9 mg — the highest phase 3 weight-loss figures recorded for any obesity drug [5][6]. For context, SURMOUNT-1 showed tirzepatide at approximately 22.5% in a comparable timeframe, and semaglutide's STEP-1 result was 14.9%.

Wegovy's cardiovascular indication separates it from retatrutide in one critical dimension: there is no MACE outcome data for retatrutide yet. Researchers tracking the full evidence picture should note that semaglutide's cardiovascular benefit is established; retatrutide's is still being evaluated in TRIUMPH-Outcomes [7]. Researchers sourcing compounds for metabolic studies can review current advanced peptide therapy protocols as a reference framework.

Sourcing Retatrutide for Research Use

Retatrutide is a research compound — not FDA-approved for human therapeutic use as of August 2026, currently completing phase 3 trials with approval anticipated in 2027. Research-use purchase is legal; it is not a scheduled substance.

For research applications, third-party COA (certificate of analysis) verification and HPLC purity documentation matter significantly at the doses used in the TRIUMPH protocols (9–12 mg/week). NextGen Peptides supplies research-grade retatrutide with assay documentation. For a broader supplier comparison, Shed is a secondary option researchers have used for peptide sourcing.

Pricing for research-grade retatrutide runs roughly $300–500/month at 12 mg/week protocols from verified vendors, compared to Wegovy's $1,300+ retail before insurance [8]. If you're evaluating the broader semaglutide research landscape, our comparison of compounded semaglutide vs brand-name Wegovy covers the compounding-route evidence in detail.

---

Frequently asked questions

How does retatrutide's weight loss compare to Wegovy in clinical trials?

Retatrutide produces approximately 24–29% mean body weight reduction at 68–80 weeks in phase 3 data, versus 14.9% for semaglutide 2.4 mg (Wegovy) at 68 weeks in the STEP-1 trial [3][4][5]. The gap holds even when controlling for trial duration — retatrutide's phase 2 result at 48 weeks (−24.2% at 12 mg) already exceeded Wegovy's 68-week benchmark [4].

Where do researchers source retatrutide in 2026?

Research-grade retatrutide is available from verified peptide suppliers including NextGen Peptides. Key sourcing criteria: third-party HPLC purity data, mass spectrometry confirmation, and transparent lot-level COA availability. Pricing at the 12 mg/week research dose runs approximately $300–500/month depending on vendor and bulk order size.

Is retatrutide legal to purchase for research use?

Retatrutide is legal to purchase as a research compound in the United States. It is not